United Orthopedics LLC
$47.9K 226 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Medicure Pharma Inc.
Medicure Pharma Inc. reported $47,834.74 across General Payments, Research, and Ownership to 304 physicians and teaching hospitals across 306 transactions.
- $47.8K Below-median payer
- All-tracks total
- 306 Above-median volume
- Transactions
- 304 Above-median reach
- Recipients
- +$12.4K
- General Payments vs PY2023
Medicure Pharma Inc. reported $47,834.74 across all CMS Open Payments tracks (General + Research + Ownership) to 304 physicians and teaching hospitals in Program Year 2024 - ranking #1362 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $27,667.20, averaging $157.35 per recipient.
How Medicure Pharma Inc.'s $47.8K all-tracks total breaks down
Medicure Pharma Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
11/100
Total payments
F
10/100
Transaction volume
F
12/100
Physician reach
F
12/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer medicure-pharma-inc Medicure Pharma Inc.
$47.8K · #1362/1,925 · 0.0% industry · PY2024
- TOT $47.8K
- RANK #1362
- SHARE 0.0%
- TXN 306
- RCP 304
- CAT 1
- GEN $27.7K
- ΔGEN +$12.4K
- TOP1 18.5%
- PY 2024
Volume peers
Nearest volume peer: United Orthopedics LLC ($47.9K)
Medicure Pharma Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Medicure Pharma Inc.'s CMS-reported General Payments increased by $12.4K (+81.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: MEDICURE PHARMA INC.PY2023: MEDICURE PHARMA INC.PY2024: Medicure Pharma Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $15,238.95
- PY2024
- $27,667.20
What the Data Shows for Medicure Pharma Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Medicure Pharma Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Compensation for Services Other Than Consulting" leads the 1-category general-payment breakdown below at $27.7K (100.0% of General Payments, 304 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 1 types of general payments, Medicure Pharma Inc.'s largest category was "Compensation for Services Other Than Consulting" at $27.7K - 100.0% of General Payments.
How Medicure Pharma Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $27.7K | 304 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $15,955.30 (57.7%) of $27,667.20 in this company's General Payments records across 214 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Medicure Pharma Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Maha Zikra
$5,126.57 across 7 reported transactions
- 2
Xu Long He
$3,078.09 across 3 reported transactions
- 3
Alan Steven Brown
$2,720.64 across 4 reported transactions
- 4
Gregory Pokrywka
$2,530.00 across 1 reported transactions
- 5
Zaid Jabbar
$2,500.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Medicure Pharma Inc.'s spend rank (#1362 of 1,925, bottom 29% by spend) and concentration rank (#1,088 of 1,838, bottom 41% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- World Class Technology Corporation : $124.1K total payments, HHI 863
- Reflow Medical Inc : $126.3K total payments, HHI 862
- Clinician's Choice Dental Products Inc. : $76.0K total payments, HHI 859
- Arineta, Inc : $1.9K total payments, HHI 859
- Responsive Arthroscopy Inc : $69.4K total payments, HHI 858
- Imperative Care, Inc : $1.2M total payments, HHI 856
- Medicure Pharma Inc. (this company) : $27.7K total payments, HHI 853
- Hexal AG : $48.3K total payments, HHI 852
- Radiometer America, Inc : $64.3K total payments, HHI 850
- Teladoc Health, Inc. : $9.9K total payments, HHI 847
- Delcath Systems : $329.6K total payments, HHI 847
- Roche Products Limited : $206.2K total payments, HHI 845
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Medicure Pharma Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Medicure Pharma Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Medicure Pharma Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Eclipse Technology Solutions Inc.
$47.7K 552 recipients
Compare payment profiles
Activ Surgical, Inc.
$48.3K 91 recipients
Compare payment profiles
Protega Pharmaceutials Inc
$48.5K 1,404 recipients
Compare payment profiles
Saxum Surgical, Inc.
$48.5K 331 recipients
Compare payment profiles
The Walman Optical Company
$47.1K 29 recipients
Compare payment profiles
Put this to use
Medicure Pharma Inc. ranks #1362 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Medicure Pharma Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.